---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-008086"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:17:01.936662+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma (MDCX) to acquire Antev Ltd. in share exchange; up to $65M in milestones

## Summary
- Consideration: 2,666,600 Medicus shares (~19% stake) plus up to US$65M contingent on FDA Phase 2/NDA approvals.
- Antev's lead asset Teverelix is a next-generation GnRH antagonist targeting acute urinary retention recurrence and high-CV-risk prostate cancer.
- Combined market opportunity estimated at ~$6B annually ($2B AUR, $4B prostate cancer).
- Transaction expected to close by end of June 2025, subject to due diligence, definitive agreement, and regulatory approvals.
- Antev shares subject to 9-month staggered lock-up and 36-month voting rights in favor of Medicus management.

## SEC filing metadata
- accession: 0001062993-25-008086
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325008086/0001062993-25-008086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325008086/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-008086
- JSON: https://secwatch.observer/filing/0001062993-25-008086.json
- Plain text: https://secwatch.observer/filing/0001062993-25-008086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.